Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma

被引：0
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2024年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：44
相关论文
共 50 条
  • [31] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [32] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Trudel, Suzanne
    Mccurdy, Arleigh
    Louzada, Martha L.
    Parkin, Stephen
    White, Darrell
    Chu, Michael P.
    Kotb, Rami
    Mian, Hira
    Othman, Ibraheem
    Su, Jiandong
    Khan, Aniba
    Gul, Engin
    Reece, Donna
    NATURE MEDICINE, 2024, 30 (02) : 543 - 551
  • [33] Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
    Wahab, Ahsan
    Rafae, Abdul
    Mushtaq, Kamran
    Masood, Adeel
    Ehsan, Hamid
    Khakwani, Maria
    Khan, Aqsa
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S185 - S186
  • [35] Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
    Pralay Mukhopadhyay
    Hesham A. Abdullah
    Joanna B. Opalinska
    Prani Paka
    Eric Richards
    Katja Weisel
    Suzanne Trudel
    Maria-Victoria Mateos
    Meletios Athanasios Dimopoulos
    Sagar Lonial
    Blood Cancer Journal, 15 (1)
  • [36] Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
    Lassiter, Grace
    Bergeron, Cole
    Guedry, Ryan
    Cucarola, Julia
    Kaye, Adam M.
    Cornett, Elyse M.
    Kaye, Alan D.
    Varrassi, Giustino
    Viswanath, Omar
    Urits, Ivan
    CURRENT ONCOLOGY, 2021, 28 (01) : 640 - 660
  • [37] Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin
    Pessach, Ilias
    Argyrakopoulou, Georgia
    Petropoulos, Fotios
    Rapti, Irene
    Danglis, Fotios
    Trajce, Enkeleida
    Chandrinou, Eleni
    LEUKEMIA & LYMPHOMA, 2023, 64 (04) : 904 - 906
  • [38] Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S504
  • [39] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
    Bird, Sarah
    Bishop, Ellouise
    Panopoulou, Katerina
    Saso, Radovan
    Mir, Farheen
    Stern, Simon
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
  • [40] Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease
    Sgherza, Nicola
    Curci, Paola
    Di Carlo, Gabriella
    Grande, Domenica
    Capozzi, Alessandro
    Ingravallo, Giuseppe
    De Marco, Luca
    Ferreri, Paolo
    Musto, Pellegrino
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1528 - 1531
12345